About
APIM Therapeutics AS is a clinical-stage biotechnology company developing peptide therapeutics that target PCNA-dependent cellular stress responses to overcome resistance in cancer treatments, with its lead drug candidate ATX-101 evaluated in Phase Ib and Phase II clinical trials for ovarian cancer and soft tissue sarcoma.
Explore APIM Therapeutics AS's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.